Search This Blog

Friday, September 4, 2026

Attovio beats, reports proof-of-concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis

 

Attovia Therapeutics reports proof-of-concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis and beats fiscal Q2 2026 EPS estimates

  • Fiscal Q2 2026 non-GAAP EPS was -0.63 with revenue $0, beating both EPS and revenue estimates.
  • Company said recent IPO proceeds extend its projected cash runway into 2030.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)